论文部分内容阅读
目的探讨不同时间应用静脉注射丙种球蛋白(IVIG)治疗川崎病的临床疗效。方法整群选择2004年1月—2015年6月间该院收治的99例川崎病患儿根据IVIG的时间分为A组(1~5 d,n=22)、B组(5~10 d,n=48)、C组(>10 d,n=29),比较各组治疗后实验室指标及丙种球蛋白无反应发生率及冠脉病变发生率。结果三组患儿治疗后血CRP、血沉及血小板比较,差异均无统计学意义(P>0.05);A组患儿丙种球蛋白无反应发生率明显高于B组、C组,差异有统计学意义(P<0.05);C组患儿冠脉病变发生率明显高于A组、B组,差异有统计学意义(P<0.05)。结论川崎病发病5-10 d静脉应用丙种球蛋白治疗时患儿的丙种球蛋白无反应发生率及冠脉病变发生率均相对较低。
Objective To investigate the clinical efficacy of intravenous gamma globulin (IVIG) in the treatment of Kawasaki disease at different times. Methods A total of 99 children with Kawasaki disease admitted to our hospital from January 2004 to June 2015 were divided into group A (1-5 days, n = 22) and group B (5-10 days) according to the time of IVIG , n = 48), and group C (> 10 d, n = 29). The laboratory indexes and the incidence of non-responsive gamma globulin and the incidence of coronary lesions in each group were compared. Results There was no significant difference in CRP, ESR and platelet count between the three groups (P> 0.05). The incidence of non-response to gamma globulin in group A was significantly higher than that in group B and C (P <0.05). The incidence of coronary artery disease in group C was significantly higher than that in group A and group B (P <0.05). Conclusions The incidence of non-responsive gamma globulin and the incidence of coronary lesions in children with Kawasaki disease onset during 5-10 d intravenous gamma globulin treatment are relatively low.